ArticleNeurology and therapy2026
Clinical Impact of High-Dose Corticosteroids on Healthcare Resource Utilization and Steroid-Related Complications in Patients with Myasthenia Gravis in Japan.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOral corticosteroids (OCS) are commonly used to control symptoms in patients with myasthenia gravis (MG). Long-term high-dose OCS use is associated with serious side effects, but the real-world clinical impact of high-dose OCS in patients with MG is not well understood. The main objectives of this study were to evaluate healthcare resource utilization and clinical complications associated with high-dose versus low-dose OCS use in Japanese patients with MG.
methodsA retrospective cohort study was performed using JMDC, a Japanese claims database. Patients with newly diagnosed MG (incident cases) were identified, and the date of the first diagnosis of MG was defined as the index date. Patients were stratified into two groups by OCS dose level (high-dose OCS ≥ 7.5 mg/day; low-dose OCS < 7.5 mg/day; based on the average dose in the population during the follow-up). Patient characteristics, treatments, long-term hospitalization (≥ 10 days cumulative per year), and corticosteroid-related complications were assessed.
resultsOf 2107 patients with an incident MG diagnosis, 576 were on OCS (high-dose OCS, 210; low-dose OCS, 366) during the follow-up period. There were no obvious differences in baseline comorbidities between the high- and low-dose OCS groups. A significant increase in long-term hospitalization was observed in the high-dose OCS versus the low-dose OCS group (adjusted odds ratio [95% CI], 1.832 [1.180, 2.845], P = 0.007). A greater proportion of patients in the high-dose OCS group versus the low-dose OCS group received ≥ 1 course per year of in-hospital intravenous immunoglobulin (34.8% vs. 15.3%), plasma exchange therapy (16.2% vs. 8.2%), and intravenous methylprednisolone pulse therapy (33.3% vs. 24.0%). The incidence of new complications such as diabetes, osteoporosis, osteoporotic fractures, neuropsychiatric disease, and sepsis was significantly (P < 0.05) higher with high- versus low-dose OCS.
conclusionUse of high-dose OCS in patients with MG was associated with adverse outcomes, including increased rates of long-term hospitalizations and clinical complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.